Sorafenib-induced Acute Pancreatitis

Han-En Wang ； Chun-Ting Chen ； Hsin-Hung Huang

《Journal of Medical Sciences》 34卷3期 (2014/06) Pp. 126-128

https://doi.org/10.4103/1011-4564.134392

並列摘要

Sorafenib was approved in 2005 for the treatment of metastatic renal cell carcinoma and advanced hepatocellular carcinoma (HCC). Acute pancreatitis is a side-effect of sorafenib usage. We present a patient with advanced HCC who presented with acute Grade D pancreatitis caused by sorafenib administration. Following the discontinuation of sorafenib, fasting, and fluid replacement, the patient's clinical manifestation of Grade D pancreatitis subsided in a short time. One month after discharge, she resumed sorafenib treatment (200 mg/day) due to disease progression. Based on this experience, resumption of sorafenib treatment appears to be safe.

並列關鍵字

Sorafenib ； pancreatitis ； hepatocellular carcinoma